title: P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.
abstract: Sequencing of p53 exons 5-8 was carried out on 51 initial superficial bladder tumors selected on the basis of high grade and/or p53 overexpression (immunohistochemistry without antigen retrieval). Fourteen point mutations in 13 tumors and one 21 bp deletion in another tumor were identified. In addition, a germ-line mutation corresponding to a previously described polymorphism was detected in exon 6, in two tumors. Mostly G-->A transitions (10) were found. Only three occurred at CpG sites, suggesting a major role for exogenous carcinogens in bladder tumorigenesis. Immunostaining for p53 and MDM2, using antigen retrieval, was carried out on the same tumors. A correlation was found between the percentage of p53-positive cells and the presence of p53 mutations (P = 0.005). No correlation was found between overexpression of p53 and MDM2 in this selected cohort of mostly high grade tumors. The presence of p53 mutations was also analyzed as a function of the smoking habits of the patients. A significant association was found between the presence of p53 point mutations and the number of years of smoking (P = 0.043). All patients with tumors carrying missense or nonsense p53 mutations had smoked for >/=30 years and if former smokers, had stopped for </=5 years. However, no correlation was found between the presence of p53 point mutations and the number of cigarettes smoked. The deletion mutation was the only one present in a tumor from a non-smoker. The data suggest that duration of exposure to carcinogens is the most critical factor in p53 mutagenesis in bladder cancer.
authors.affiliation: Centre de recherche en cancérologie de l'Université Laval, Pavillon L'Hôtel-Dieu de Québec, Centre Hospitalier Universitaire de Québec, 10 MacMahon, Québec G1R 2J6, Canada.
authors.forename: H
authors.initials: H
authors.lastname: LaRue
authors.forename: P
authors.initials: P
authors.lastname: Allard
authors.forename: M
authors.initials: M
authors.lastname: Simoneau
authors.forename: C
authors.initials: C
authors.lastname: Normand
authors.forename: C
authors.initials: C
authors.lastname: Pfister
authors.forename: L
authors.initials: L
authors.lastname: Moore
authors.forename: F
authors.initials: F
authors.lastname: Meyer
authors.forename: B
authors.initials: B
authors.lastname: Têtu
authors.forename: Y
authors.initials: Y
authors.lastname: Fradet
mesh_terms: D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009687:Nuclear Proteins; D017354:Point Mutation; D011518:Proto-Oncogene Proteins / Q000032:analysis; D051736:Proto-Oncogene Proteins c-mdm2; D017422:Sequence Analysis, DNA; D012907:Smoking / Q000009:adverse effects* / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D001749:Urinary Bladder Neoplasms / Q000209:etiology / Q000235:genetics*
chemical_list: D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2